Literature DB >> 17113155

A family study of co-morbidity between generalized social phobia and generalized anxiety disorder in a non-clinic sample.

Helen F Coelho1, Peter J Cooper, Lynne Murray.   

Abstract

BACKGROUND: High rates of co-morbidity between Generalized Social Phobia (GSP) and Generalized Anxiety Disorder (GAD) have been documented. The reason for this is unclear. Family studies are one means of clarifying the nature of co-morbidity between two disorders.
METHODS: Six models of co-morbidity between GSP and GAD were investigated in a family aggregation study of 403 first-degree relatives of non-clinical probands: 37 with GSP, 22 with GAD, 15 with co-morbid GSP/GAD, and 41 controls with no history of GSP or GAD. Psychiatric data were collected for probands and relatives. Mixed methods (direct and family history interviews) were utilised.
RESULTS: Primary contrasts (against controls) found an increased rate of pure GSP in the relatives of both GSP probands and co-morbid GSP/GAD probands, and found relatives of co-morbid GSP/GAD probands to have an increased rate of both pure GAD and co-morbid GSP/GAD. Secondary contrasts found (i) increased GSP in the relatives of GSP only probands compared to the relatives of GAD only probands; and (ii) increased GAD in the relatives of co-morbid GSP/GAD probands compared to the relatives of GSP only probands. LIMITATIONS: The study did not directly interview all relatives, although the reliability of family history data was assessed. The study was based on an all-female proband sample. The implications of both these limitations are discussed.
CONCLUSIONS: The results were most consistent with a co-morbidity model indicating independent familial transmission of GSP and GAD. This has clinical implications for the treatment of patients with both disorders.

Entities:  

Mesh:

Year:  2006        PMID: 17113155     DOI: 10.1016/j.jad.2006.10.001

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  7 in total

Review 1.  Family factors in the development and management of anxiety disorders.

Authors:  Ronald M Rapee
Journal:  Clin Child Fam Psychol Rev       Date:  2012-03

2.  Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR).

Authors:  L J Strug; R Suresh; A J Fyer; A Talati; P B Adams; W Li; S E Hodge; T C Gilliam; M M Weissman
Journal:  Mol Psychiatry       Date:  2008-07-29       Impact factor: 15.992

3.  Association of respondent psychiatric comorbidity with family history of comorbidity: Results from the National Epidemiologic Survey on Alcohol and Related Conditions-III.

Authors:  Jeesun Jung; Risë B Goldstein; Bridget F Grant
Journal:  Compr Psychiatry       Date:  2016-08-08       Impact factor: 3.735

4.  The validity of the family history screen for assessing family history of mental disorders.

Authors:  B J Milne; A Caspi; R Crump; R Poulton; M Rutter; M R Sears; T E Moffitt
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-01-05       Impact factor: 3.568

5.  How should we construct psychiatric family history scores? A comparison of alternative approaches from the Dunedin Family Health History Study.

Authors:  B J Milne; T E Moffitt; R Crump; R Poulton; M Rutter; M R Sears; A Taylor; A Caspi
Journal:  Psychol Med       Date:  2008-03-26       Impact factor: 7.723

6.  Stimulus-reinforcement-based decision making and anxiety: impairment in generalized anxiety disorder (GAD) but not in generalized social phobia (GSP).

Authors:  J DeVido; M Jones; M Geraci; N Hollon; R J R Blair; D S Pine; K Blair
Journal:  Psychol Med       Date:  2008-12-22       Impact factor: 7.723

7.  Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders.

Authors:  Karina Blair; Jonathan Shaywitz; Bruce W Smith; Rebecca Rhodes; Marilla Geraci; Matthew Jones; Daniel McCaffrey; Meena Vythilingam; Elizabeth Finger; Krystal Mondillo; Madeline Jacobs; Dennis S Charney; R J R Blair; Wayne C Drevets; Daniel S Pine
Journal:  Am J Psychiatry       Date:  2008-05-15       Impact factor: 18.112

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.